Pricing Availability   Qty

15% Off Limited-time Savings on Your Reagents, Assays, and Kits
Now through September 27th, you can save 15% on Bio-Techne reagents, assays, and kits (including Novus, Tocris, and R&D Systems). Use promotion code SAVE15 at checkout on orders over $1,000. See terms and conditions for offer details.

Description: Reduces Aβ aggregation and fibrillogenesis; neuroprotective and neurotrophic peptide
Purity: ≥95% (HPLC)
Literature (2)

Biological Activity for Semax

Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH) (4-10). It increases hippocampal BDNF and TrkB expression and levels in vivo. Semax regulates cortical nitric oxide (NO) and lipid peroxidation and is neuroprotective in a rat model of global ischemia. Semax sequesters copper ions and interacts directly with Aβ:Cu2+ oligomers leading to reduced amyloid β protein (Aβ) aggregation and fibrillogenesis. Semax increases viability of d-SH-SY5Y cells pre-incubated with Aβ1-42 oligomers.

Technical Data for Semax

M. Wt 813.93
Formula C37H51N9O10S
Sequence MEHFPGP
Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 80714-61-0
PubChem ID 9811102
Smiles O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC2=CC=CC=C2)C(N3[C@@H](CCC3)C(NCC(N4[C@@H](CCC4)C(O)=O)=O)=O)=O)=O)=O)[C@H](CCSC)N

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Semax

Solubility Soluble to 2 mg/ml in water

References for Semax

References are publications that support the biological activity of the product.

Bashkatova (2001) Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia. Brain Res. 894 145 PMID: 11245825

Dolotov et al (2006) Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 1117 54 PMID: 16996037

Sciacca et al (2022) Semax, a synthetic regulatory peptide, affects copper-induced Abeta aggregation and amyloid formation in artificial membrane models. ACS Chem.Neurosci. 13 486 PMID: 35080861

If you know of a relevant reference for Semax, please let us know.

View Related Products by Target

Keywords: Semax, Semax supplier, peptides, analogs, adrenocorticotropic, hormone, hippocampal, BDNF, trkB, neuroprotective, global, ischemia, amyloid, beta, Aβ, ABeta, aggregation, inhibits, fibrillogenesis, Alzheimers, Amyloid, Beta, Peptides, Other, RTKs, 7712, Tocris Bioscience

Citations for Semax

Citations are publications that use Tocris products.

Currently there are no citations for Semax. Do you know of a great paper that uses Semax from Tocris? Please let us know.

Reviews for Semax

There are currently no reviews for this product. Be the first to review Semax and earn rewards!

Have you used Semax?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Neurodegeneration Product Guide

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Alzheimer's Poster

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.